Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Exogenous Surfactant Treatment in Children with ARDS
1,Paediatric Intensive Care University Hospital A. Gemelli
*Corresponding Author(s): LUCA TORTOROLO E-mail: luca.tortorolo@gmail.com
Since the Food and Drug Administration (FDA) approved exogenous surfactant in the early 90s for the treatment of neonates with Hyaline Membrane Disease (HMD), many studies have focused on enlarging its indications for others types of lung injuries and for other age groups. Although in the past 20 years no studies have shown clear results about the efficacy of exogenous surfactant treatment in paediatric Acute Respiratory Distress Syndrome (ARDS), many of them were able to point out and better define very important aspects of this treatment like dosage, timing, ways of administration and usage of different types of surfactant (natural and synthetic). In this review we retrace the development of studies looking at the role of exogenous surfactant treatment in paediatric ARDS.
surfactant, ARDS, bron-choalveolar lavage
LUCA TORTOROLO,ORAZIO GENOVESE,ENZO PICCONI,MARCO PIASTRA,GIORGIO CONTI. Exogenous Surfactant Treatment in Children with ARDS. Signa Vitae. 2013. 8(2);9-14.
1. Adrienne R. Management of acute lung injury and acute respiratory distress syndrome in children. Crit Care Med 2009;37(8):2448-54.
2. Bush A. Up Date in pediatric lung disease 2008. Am J Respir Crit Care Med 2009;179:637-49.
3. Dahlem P, van Aalderen Wm, Bos AP. Pediatric acute lung injury. Pediatric Respir Rev 2007;8:348-62.
4. Lewis JF, Brackenbury A. Role of exogenous surfactant in acute lung injury. Crit Care Med 2003;31(s):324-8.
5. Tashiro K, Wen-Zhi L, Keisuke Y, Yutaka M, Tsutomu K. Surfactant replacement reverses respiratory failure induced by intratracheal endo-toxin in rats. Crit Care Med 1995;23:149-56.
6. Scholtes U, Wiegand N, Zwirner J, Herting E . Influence of porcine natural modified surfactant on chemotaxis and oxidative metabolism of polymorphonuclear leukocytes. Immunobiol 2002;205:290–302.
7. Levine AM, Whitsett JA, Gwozdz JA, Richardson TR, Fisher JH, Burhans MS, et al. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J Immunol 2000;165:3934–40.
8. Ito Y, Veldhuizen RA, Yao LJ, Mccaig LA, Bartlett AJ, Lewis JF. Ventilation strategies affect surfactant aggregate conversion in acute lung injury. Am J Respir Crit Care Med 1997;155(2):493-9.
9. Tahvanainen J, Hallman M. Surfactant abnormality after endotoxin-induced lung injury in guinea-pigs. AJP 2002;283:655-83.
10. Skelton R, Holland P, Darowski M, Chetcuti PA, Morgan LW, Harwood JL. Abnormal surfactant composition and activity in severe bronchi-litis. Acta Paediatr 1999;88:942-46.
11. Kerr MH, Paton Jm. Surfactant Protein Levels in Severe Respiratory Syncytial Virus infection. Am J Respir Crit Care Med 1999;159:1115-8.
12. Levine AM, Lotze A, Stanley S, Stroud C, O'Donnell R, Whitsett J, Pollack M. Surfactant content in children with inflammatory lung disease. Crit Care Med 1996; 24:1062-7.
13. Willson DF, Chess PR, Notter RH. Surfactant for pediatric acute lung injury. Pediatric Clin North Am 2008;55:545-75.
14. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967;ii:319–23.
15. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012 Jun 20;307(23):2526-33.
16. Brower RG, Ware LB, Berthiaume Y, Matthay MA. Treatment of ARDS. Chest 2001;120:1347–67.
17. Wirbelauer J, Speer CP. The role of surfactant treatment in preterm infants and term newborns with acute respiratory distress syndrome. J Perinatol 2009;29:18–22.
18. Pérez-Gil J. Structure of pulmonary surfactant membranes and films: The role of proteins and lipid–protein interactions. Bioch Biophy Acta 2008;1778:1676-95.
19. Davidson WJ, Dorscheid D, Spragg R, Schulzer M, Mak E, Ayas NT. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis. Crit Care 2006;10:41.
20. Willson DF, Thomas NJ, Markovitz BP, Bauman LA, Dicarlo JV, Pon S, et al. Effect of Exogenous Surfactant (Calfactant) in Pediatric Acute Lung Injury. JAMA 2005;293:470-6.
21. Luchetti M, Ferrero F, Gallini C, Natale A, Pigna A, Tortorolo L, et al. Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Pediatr Crit Care Med 2002;3:261-66.
22. Duffett M, Choong K, Ng V, Randolph A, Cook DJ. Surfactant therapy for acute respiratory failure in children: a systematic review and meta-analysis. Crit Care 2007;11:66.
23. Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventós AA, et al. Aerosolized Surfactant in Adults with Sepsis-Induced Acute Respiratory Distress Syndrome. N Engl J Med 1996;334:1417-22.
24. Cochrane G, Revak S. Surfactant lavage treatment in a model of respiratory distress syndrome. Chest 1999;116:85-6.
25. Gommers D, Eijking P, So Kl, van’t Veen A, Lachmann B. Bronchoalveolar lavage with a diluted surfactant suspension prior to surfactant instillation improves the effectiveness of surfactant therapy in experimental acute respiratory distress syndrome (ARDS). Inten Care Med 1998;24:494-500.
26. Cochrane G. Lavage in LPS lung of rabbitt. Chest 1999;116:85-6.
27. Balaraman J, Meister J, Ku TL, Sood SL, Tam E, Killeen J, et al. Lavage administration of dilute surfactants after acute lung injury in neonatal piglets. Am J resp crit care med 1998;158:12-7.
28. Strohmaier A. Bronchoscopic lavage in piglets. Crit Care Med 2005;33:2286-93.
29. Dargaville PA, Mills JF, Headley BM, Chan Y, Coleman L, Loughnan PM, et al. Therapeutic Lung Lavage in the Piglet Model of Meconium Aspiration Syndrome. Am J Resp Crit Care Med 2003;168:456-63.
30. Tortorolo L, Chiaretti A, Pulitano S, Genovese O, Conti G. Diluted porcine surfactant lung lavages in children with severe ARDS. Signa Vitae 2009;4:16-9.
31. Wiswell TE, Smith RM, Katz LB, Mastroianni L, Wong DY, Willms D, et al. Bronchopulmonary Segmental Lavage with Surfaxin (KL4-Surfactant) for Acute Respiratory Distress Syndrome. Am J Resp Crit Care Med 1999;160:1188-95.
32. Nakamura CT, Ripka JF, Mcveigh K, Kapoor N, Keens TG. Bronchoscopic instillation of surfactant in acute respiratory distress syndrome. Ped Pulmol 2001;31:317–20.
33. Marraro GA, Lucchetti M, Spada C, Galassini E, Giossi M, Piero AM. Selective medicated (normal saline and exogenous surfactant) bro-choalveolar lavage in severe aspiration syndrome in children. Ped Crit Care Med 2007;8:505-6.
34. Dargaville PA, Copnell B, Mills JF, Haron I, Lee JKF, Tingay DJ, et al. Randomized Controlled Trial of Lung Lavage with Dilute Surfactant for Meconium Aspiration. Synd J Ped 158;3:383-9.
35. Meltem U, Ozlem G, Tolga Altug S, Adnan N, Faruk A. Surfactant Replacement Therapy in a Pediatric Near-Drowning Case in Manure. Ped Em Care 2002;28:913-4.
36. Sen S, Tung K, Palmieri T, Greenhalgh DJ. Surfactant therapy for acute respiratory distress in severe pediatric burn injury: a case series. J Burn Care Res 2012 Mar-Apr;33(2):e88-91.
37. Van Der Bleek J, Plötz FB, Van Overbeek FM, Heikamp A, Beekhuis H, Wildevuur CRH, et al. Distribution of Exogenous Surfactant in Rabbits with Severe Respiratory Failure: The Effect of Volume. Ped Research 1993;34:154–8.
38. Berggren E, Liljedahl M, Winbladh B, Andreasson B, Curstedt T, Robertson B, et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paed 2000;89:460–4.
39. El-Gendy N, Kaviratna A, Berkland C, Dhar P. Delivery and performance of surfactant replacement therapies to treat pulmonary disorders. Therap Del 2013;4:951.
40. Göpel W, Kribs A, Ziegler A, Laux R, Hoehn T, Wieg C, et al. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet 2011;378:9803-1627.
41. Mingarro I, Lukovic D, Vilar M, Perez-Gil J. Synthetic Pulmonary Surfactant Preparations: New Developments and Future Trends. Curr Med Chem 2008;15:393-403.
42. Cogo1 PE, Carnielli VP, Bunt JEH, Badon T, Giordano G, Zacchello F, et al. Endogenous Surfactant Metabolism in Critically Ill Infants Measured with Stable Isotope Labeled Fatty Acids. Ped Research 1999;45:242–6.
43. Lewis JF, Veldhuizen RAW. Analyzing Surfactant Metabolism in Humans. Am J Resp Crit Care Med 2004;170:1-3.
44. Cavicchioli P, Zimmermann LJI, Cogo PE, Badon T, Giordano G, Torresin M, et al. Endogenous surfactant turnover in preterm infants with respiratory distress syndrome studied with stable isotope lipids. Am J Resp Crit Care Med 2001;163:55-60.
45. Baudouin SV. Exogenous Surfactant Replacement in ARDS- One day, Some day or Never? New Eng J Med 2004;351:853-5.
46. Willson DF, Thomas NJ, Tamburro R, Truemper E. Pediatric Calfactant in Acute Respiratory Distress Syndrome Trial. Pediatr Crit Care Med 2013;14:657-65.
47. Cursted T, Calkovska A, Johanson J. New generation of syntetic surfactant. Neonatology 2013;103:327-30.
Top